ArticleFrontiers in medicine2026
Pediatric cardiomyopathy in a resource-limited setting: clinical characteristics and determinants of medium-term outcomes.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Pediatric cardiomyopathy is the leading indication for cardiac transplantation in children. However, data on its prevalence and outcomes mainly comes from developed countries, with only a scarce amount of information about its status in low- and middle-income countries. Purpose: This study aimed to characterize the clinical presentation, echocardiographic features, and outcomes of pediatric cardiomyopathy at a tertiary care center in a developing country. Methods: We conducted a retrospective review of children diagnosed with cardiomyopathy before 18 years of age at a single tertiary cardiac center over a 20-year period. Mortality at 5 years following diagnosis was assessed as a binary outcome. Univariable and multivariable logistic regression analyses were performed to identify factors associated with mortality. Results: A total of 244 children were included (mean age at diagnosis 5.9 ± 5.7 years; 57% male). Dilated cardiomyopathy was the most common phenotype, identified in 153 patients (62.7%), followed by hypertrophic cardiomyopathy in 74 (30.3%), restrictive cardiomyopathy in 10 (4.1%), and left ventricular non-compaction cardiomyopathy in 7 (2.9%). No cases of arrhythmogenic right ventricular cardiomyopathy were identified. Half of the cohort was asymptomatic at presentation and diagnosed incidentally. Presumptive myocarditis/inflammatory etiologies predominated overall and in the DCM subgroup, whereas familial/genetic etiologies predominated among patients with HCM. The 5-year mortality rate was 13.1%, with the majority of deaths occurring in children with dilated cardiomyopathy. In the overall cohort multivariable model, severely reduced left ventricular systolic function at diagnosis (adjusted OR 3.06, 95% CI 1.36-6.85) and pulmonary hypertension at diagnosis (adjusted OR 2.64, 95% CI 1.45-4.80) were the only independent predictors of mortality. Cardiomyopathy subtype, age at diagnosis, sex, and arrhythmias were not independently associated with outcome. In the In the DCM subgroup, pulmonary hypertension remained independently associated with mortality (adjusted OR 2.77, 95% CI 1.42-5.40), while severe systolic dysfunction showed a borderline association (adjusted OR 2.54, 95% CI 1.00-6.44). Conclusion: In this cohort, pediatric cardiomyopathy was characterized by a high prevalence of incidental diagnoses and a predominance of dilated phenotypes. Severe systolic dysfunction and pulmonary hypertension were the principal determinants of medium-term mortality, outweighing demographic and phenotypic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.